<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second most common cause of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in both men and women in the majority of developed countries </plain></SENT>
<SENT sid="1" pm="."><plain>Molecular tests of blood could potentially provide this ideal screening tool </plain></SENT>
<SENT sid="2" pm="."><plain>AIM: Our objective was to assess the usefulness of serum markers and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels in the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: In a prospective study, we measured <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels of 13 markers (carbonic anhydrase, guanylyl cyclase C, plasminogen activator inhibitor, matrix metalloproteinase 7 (MMP7), urokinase-type plasminogen activator receptor (uPAR), urokinase-type plasminogen activator, survivin, tetranectin, vascular endothelial growth factor (VEGF), cytokeratin 20, thymidylate synthase, cyclooxygenase 2 (COX-2), and CD44) and three proteins in serum (alpha 1 antitrypsin, carcinoembryonic antigen (CEA) and activated C3 in 42 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 33 with <z:mpath ids='MPATH_458'>normal</z:mpath> colonoscopy results </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Alpha 1-antitrypsin was the serum marker that was most useful for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> diagnosis (1.79 ± 0.25 in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> group vs 1.27 ± 0.25 in the control group, P&lt;0.0005) </plain></SENT>
<SENT sid="5" pm="."><plain>The area under the ROC curve for alpha 1-antitrypsin was 0.88 (0.79-0.96) </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression levels of five markers were statistically different between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases and controls: those for which the ROC area was over 75% were MMP7 (0.81) and tetranectin (0.80), COX-2 (0.78), uPAR (0.78) and carbonic anhydrase (0.77) </plain></SENT>
<SENT sid="7" pm="."><plain>The markers which identified early stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (Stages I and II) were alpha 1-antitrypsin, uPAR, COX-2 and MMP7 </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Serum alpha 1-antitrypsin and the levels of <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of MMP7, COX-2 and uPAR have good diagnostic accuracy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, even in the early stages </plain></SENT>
</text></document>